## Core Concept
The question tests the understanding of neurotransmitter release and degradation, specifically focusing on **acetylcholine (ACh)**, a crucial neurotransmitter in both the central and peripheral nervous systems. Acetylcholine levels in the synaptic cleft can be influenced by its release from the presynaptic neuron and its degradation by specific enzymes. The primary enzyme responsible for acetylcholine degradation is **acetylcholinesterase (AChE)**, which breaks down ACh into choline and acetate.

## Why the Correct Answer is Right
The correct answer, **neostigmine**, is a **reversible cholinesterase inhibitor**. By inhibiting acetylcholinesterase, neostigmine prevents the breakdown of acetylcholine in the synaptic cleft. This inhibition leads to an accumulation of acetylcholine, increasing its concentration and prolonging its action on postsynaptic receptors. Neostigmine and other cholinesterase inhibitors are used clinically to enhance cholinergic transmission, for example, in the treatment of myasthenia gravis.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is incorrect because it would not directly increase acetylcholine levels; instead, it could potentially decrease them by enhancing its breakdown or reducing its release.
- **Option B:** This option is incorrect as it does not accurately describe a mechanism that would increase acetylcholine levels in the synaptic cleft.
- **Option D:** This option is incorrect because, similar to Option A, it does not describe a mechanism that would lead to increased levels of acetylcholine in the synaptic cleft.

## Clinical Pearl / High-Yield Fact
A key point to remember is that **acetylcholinesterase inhibitors** like neostigmine, pyridostigmine, and donepezil increase acetylcholine levels by preventing its breakdown. These drugs have various clinical applications, including the management of **myasthenia gravis** (neostigmine, pyridostigmine) and **Alzheimer's disease** (donepezil).

## Correct Answer: B. Neostigmine